BOSTON, June 26 /PRNewswire-FirstCall/ -- Perceptive Informatics, the technology subsidiary of PAREXEL International Corporation , has appointed Mr. Wade Wirta as Vice President of its worldwide Clinical Interactive Voice Response Systems (IVRS) operations.
Perceptive Informatics provides innovative technology-based solutions designed to help bio/pharmaceutical companies accelerate clinical development. Mr. Wirta brings extensive experience in clinical IVRS and supply chain management as well as in the development of global, enterprise-wide IVRS software solutions supporting clinical trial execution.
“Today, a significant proportion of clinical trials employ sophisticated Interactive Voice Response Systems (IVRS) to manage data collection, patient randomization and clinical supply inventories,” said Todd Joron, Corporate Vice President and General Manager of Perceptive Informatics. “We expect Mr. Wirta’s invaluable combination of clinical trial and technology expertise to further enhance Perceptive’s ability to meet the needs of our IVRS clients.”
“As the pharmaceutical and biotech industry faces intense pressure for more efficient clinical trial conduct and resource management, the need for more robust IVR platforms becomes increasingly important,” said Mr. Wade Wirta, Vice President of Clinical IVRS, Perceptive. “As part of one of the world’s leading CROs, Perceptive Informatics is uniquely positioned with its set of integrated technology offerings and I am excited to be a part of this dynamic organization.”
Prior to joining PAREXEL, Mr. Wirta spent more than 13 years with Pfizer, Inc. In his most recent position as Director of Pfizer’s Supply Chain Informatics group, Mr. Wirta was responsible for driving the IT strategy for supply chain products and services across the clinical drug development phases.
Mr. Wirta holds a bachelor’s degree in computer science from the University of Maine at Orono in Maine and a certification in Project Management from the British Computing Society. He is based at the Lowell, Massachusetts location of Perceptive Informatics.
About Perceptive Informatics, a PAREXEL Company
PAREXEL’s Technology Division, Perceptive Informatics, combines clinical knowledge, quality and regulatory experience with advanced technology to decrease time to market, risk and cost associated with clinical trials. Perceptive’s portfolio includes Medical Imaging, Clinical Trial Management Systems (CTMS), Interactive Voice Response Systems (IVRS & IWRS), and Integration Services as well as web-based portal solutions, tracking tools, electronic diaries and investigator database solutions. Perceptive offers medical imaging services to rapidly and objectively assess the safety and efficacy of new drugs, biologics and medical devices in clinical trials. The IMPACT(TM) solution is Perceptive’s market-leading CTMS product with 25,000 users worldwide, and Perceptive’s INITIATOR(TM) trial management product targets the needs of Phase I units. For more information about Perceptive Informatics, visit www.perceptive.com.
About PAREXEL International
PAREXEL International Corporation is a leading global bio/pharmaceutical services organization, providing a broad range of knowledge-based contract research, medical marketing and consulting services to the worldwide pharmaceutical, biotechnology and medical device industries. Committed to providing solutions that expedite time-to-market and peak-market penetration, PAREXEL has developed significant expertise across the development and commercialization continuum, from drug development and regulatory consulting to clinical pharmacology, clinical trials management, medical education and reimbursement. Headquartered near Boston, Massachusetts, PAREXEL operates in 55 locations throughout 43 countries around the world, and has over 6,315 employees. For more information about PAREXEL International visit www.PAREXEL.com.
This release contains “forward-looking” statements regarding future results and events. For this purpose, any statements contained herein that are not statements of historical fact may be deemed forward-looking statements. Without limiting the foregoing, the words “believes,” “anticipates,” “plans,” “expects,” “intends,” “appears,” “estimates,” “projects,” “targets,” and similar expressions are also intended to identify forward-looking statements. The forward-looking statements in this release involve a number of risks and uncertainties. The Company’s actual future results may differ significantly from the results discussed in the forward-looking statements contained in this release. Important factors that might cause such a difference include, but are not limited to, risks associated with: actual operating performance; actual expense savings and other operating improvements resulting from recent restructurings; the loss, modification, or delay of contracts which would, among other things, adversely impact the Company’s recognition of revenue included in backlog; the Company’s dependence on certain industries and clients; the Company’s ability to win new business, manage growth and costs, and attract and retain employees; the Company’s ability to complete additional acquisitions and to integrate newly acquired businesses or enter into new lines of business; the impact on the Company’s business of government regulation of the drug, medical device and biotechnology industry; consolidation within the pharmaceutical industry and competition within the biopharmaceutical services industry; the potential for significant liability to clients and third parties; the potential adverse impact of health care reform; and the effects of exchange rate fluctuations and other international economic, political, and other risks. Such factors and others are discussed more fully in the section entitled “Risk Factors” of the Company’s Quarterly Report on Form 10-Q for the period ended March 31, 2007 as filed with the SEC on May 9, 2007, which “Risk Factors” discussion is incorporated by reference in this press release. The forward-looking statements included in this press release represent the Company’s estimates as of the date of this release. The Company specifically disclaims any obligation to update these forward-looking statements in the future. These forward-looking statements should not be relied upon as representing the Company’s estimates or views as of any date subsequent to the date of this press release.
PAREXEL is a registered trademark of PAREXEL International Corporation, and Perceptive Informatics is a trademark of Perceptive Informatics, Inc. All other names or marks may be registered trademarks or trademarks of their respective business and are hereby acknowledged.
Contacts: Karen Wills, Rebecca Passo Vice President, Corporate Marketing SHIFT Communications PAREXEL International Tel: +617-779-1817 Tel: +781-434-5301 Email: rpasso@shiftcomm.com Email: Karen.Wills@PAREXEL.com
PAREXEL
CONTACT: Karen Wills, Vice President, Corporate Marketing, PAREXELInternational, +1-781-434-5301, or Karen.Wills@PAREXEL.com, or RebeccaPasso, SHIFT Communications for PAREXEL International, +1-617-779-1817, orrpasso@shiftcomm.com
